GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
NCT06003153 on ClinicalTrials.gov · last registry update 2026-07-08
Recruiting now, toward 125 participants. Due to report 31 May 2027, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Insulin response to oral semaglutide treatment. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 12 March 2024 — 2 years so far. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P4
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Other
- Enrollment
- 125
- Started
- 2024-03-12
- Primary completion
- 2027-05-31 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Insulin response to oral semaglutide treatment
Conditions studied
Genetic Predisposition · Metabolic Diseases · Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.